Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

Cleveland Clinic: Kirurgi gav fler långsiktiga fördelar än GLP-1-läkemedel

Metabol kirurgi minskade riskerna för död, hjärtsjukdom, njursvikt och ögonskador mer än GLP-1-läkemedel under en tioårsperiod. Det enligt en ny studie från Cle...

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

FDA approves Gilead’s HIV injection: “Historic day”

Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...

Venomaid's rapid test aims to find the right snake bite treatment

Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom ca...

Reduced heat transfer to the media with media-separated valves

In laboratory automation, many liquids are used that react sensitively to heat. One possible factor for the transfer of heat to the fluid are media-separated so...

Discover the new ZEISS Axioscan 7 clinical

Your digital slide scanner for diagnostics & clinical research.

Falska studiedeltagare – ett växande hot mot forskningen

Digital rekrytering blir allt vanligare vid hälsorelaterad forskning, men samtidigt ökar problemet med falska deltagare. Det hotar både resultatens tillförlitli...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Virology professor on the threat from X: ”The next pandemic could be worse“

The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Will the FDA’s new transparency policy extend to medical devices? (Part 1)

In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...

Digitalt lyft för Life Science Sweden och resten av Nordiske Medier

Life Science Sweden är en av många branschtidningar som ges ut av B2B-förlaget Nordiske Medier, som nu kan erbjuda alla läsare en mer modern och användarvänlig plattform.

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee

Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretar...

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

Accelerate your Research with AI-Powered Image Analysis

Comprehensive eBook from ZEISS.

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...